Circulating IL-6, Clusterin and Irisin in Obese Subjects

Study Overview
=================
Brief Summary
-----------------
evaluate the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes who had different classes of obesity and their sexual dimorphism also identify the association of IL-6, clusterin and irisin with insulin resistance.

Detailed Description
-----------------
Aim: Firstly, this study aimed at assessing the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes who had different classes of obesity and evaluating their sexual dimorphism and secondly evaluate the association of IL-6, clusterin and irisin with insulin resistance. Method: This study was conducted on 176 non-diabetic subjects of both sexes. Participants were classified according to their sex into two groups; the male and female groups. The male group (88 men) was classified according to BMI into; group 1 (22 lean men), group 2 (22 class I obese men), group 3 (22 class II obese men), and group 4 (22 class III obese men). The female group (88 women) was also classified according to BMI exactly as the male group. Fasting blood glucose, fasting insulin, lipid panel, serum IL-6, clusterin and irisin levels were measured. One-way analysis of variance followed by Tukey's as post hoc test was used for comparison of variables.

Official Title
-----------------
Circulating IL-6, Clusterin and Irisin in Obese Subjects With Different Grades of Obesity: Association With Insulin Resistance and Sexual Dimorphism

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Diagnostic Test: IL-6, Clusterin, Irisin Level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Female and Male Age matched adult non-diabetic non-smoker males and females' Exclusion Criteria: smokers, subjects with a history of diabetes mellitus, liver, renal, thyroid, inflammatory diseases, and females on contraceptives pills. Patients on medications that can interfere with glucose or lipid metabolism (corticosteroids, anti-hyperlipidemics, non-selective beta blockers, thiazides, etc.) and subjects with organic causes of obesity were also excluded from this study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1 Male<br>group 1 (22 lean men), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 2 Male<br>group 2 (22 class I obese men), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 3 Male<br>group 3 (22class II obese men), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 4 Male<br>group 4 (22 class III obese men). | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 1 Female<br>group 1 (22 lean women), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 2 Female<br>group 2 (22 class I obese women), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 3 Female<br>group 3 (22 class II obese women), | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|
| Group 4 Female<br>group 4 (22 class III obese women). | Diagnostic Test: IL-6, Clusterin, Irisin Level<br>* Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance | by homeostasis insulin resistance index (fasting insulin (μIU/ml) times fasting glucose (mg/L) divided by 405 ) | 18 months | 
| IL- 6 | blood level of IL-6 | 18 Months | 
| Clusterin | blood level of Clusterin | 18 Months | 
| Irisin | blood level of Irisin | 18 Months | 
| Lipid profile | Plasma triglycerides and total cholesterol were measured by enzymatic colorimetric method. High-density lipoprotein cholesterol (HDL-C) was measured by precipitation method. Low density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula | 18 Months |